Background
• Enbrel® (etanercept) is approved by Health Canada for several indications: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis
• Rheumatoid arthritis (RA) is an autoimmune disease affecting patients' tissue lining and joints (Bykerk, 2012) • Psoriasis (PsO) is an immune-mediated disease affecting the skin (National Psoriasis Association, 2013) • In Canada, most patients receive reimbursement for their prescription medications either through private drug plans, or provincially managed public drug plans
• In Ontario, patients 65 years of age or greater or on social assistance qualify for a public drug plan
• In Quebec, those without a private drug plan receive public drug plan coverage • Amgen's patient assistance program for Enbrel® (Enliven®), suggests that some patients experience a delay in accessing Enbrel® when transitioning from private to public drug plans
• Currently, there is limited information on patient treatment patterns during their transition from private to public plans, with a prior study indicating that approximately two-thirds of senior patients show a reimbursement gap in Enbrel® when transitioning between payers (Millson et al, CAPT Nov. 2014) 
Limitations
• Measurement of Reimbursement Gap: Days of therapy information in the IMS Brogan LifeLink® database for biologic therapy can be unreliable. Therefore, improbable values were replaced by standardized doses.
• Misclassified Indication: Diagnosis codes are not available in the IMS Brogan LifeLink® database. Therefore, indications were inferred using an algorithm based on prescription history and prescribing physician specialties. There is potential for misclassification, but this should not affect the primary objective.
• Enliven® Participants: We are unable to determine whether a patient was part of the EnLiven® patient support program which provides assistance to patients as they navigate the reimbursement process. Since >80% of patients receiving Enbrel® are enrolled in the program, bias comparing patients receiving Enliven® support to other Enbrel® patients would be limited.
• Geographic: This study is restricted to Ontario and Quebec. Therefore, these results may not be generalizable to the entire Canadian population.
• Missing Data: Irregularly reporting pharmacies were excluded as to not misclassify an unreported prescription as a reimbursement gap. Similarly, we excluded patients with missing demographic variables. • Patients transitioning to non-Enbrel® therapy following the transition to a public plan showed longer reimbursement gaps than those who continued on Enbrel® therapy
Conclusions •
• 23% of Enbrel® patients revert back to DMARD therapy on a public plan even after previously requiring a biologic therapy, which has the potential to impact patient outcomes 
Study Cohort Analysis
• 474 patients were identified who met the inclusion/exclusion criteria ( Figure 1) • Of those patients, 51% were from Ontario, 60% were female, and 70% were younger than 65 years of age ( 
Lines of Therapy Progression
• Of the 397 patients with one year follow-up, 54% remained on their first public plan line, 15% progressed to a second-line, 26% progressed to a third-line, and 5% progressed to a fourthline or greater
• Most patients continued with Enbrel® (61%) after transitioning to a public plan, followed by DMARDs (23%), Enbrel® with DMARDs (11%), and other biologics or other biologics with DMARDs (5%) (Figure 3) • Of the patients whose first public Rx was a DMARD, 69%
switched to Enbrel® or added Enbrel® to their DMARD • For patients who continued Enbrel® within the analysis period, the median reimbursement gap decreased to 15 days (95% CI [11, 23] Patients' pharmacy consistently reports within the full study period n = 5,395
Patients have at least one public claim in the analysis period n = 840
Patients discontinued therapy n = 42
Indication of discontinued patients RA -n= 31 Psoriasis -n = 7 Unknown -n = 2* Patients continued with a DMARD or biologic n = 432
Patients with at least one year follow-up from index date n = 397
Patients have no public claims in the look-back period n = 3,601
Patients have no private claims after the first public claim n = 474 Research funded by Amgen Inc.
